Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head

This three-way comparison is part of Weight Loss Rankings' living editorial database — 1,050+ research articles and 550+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

On April 1, 2026, the FDA approved Foundayo (orforglipron), the first oral non-peptide GLP-1 receptor agonist for chronic weight management^[1]. It entered a market dominated by two injectable heavyweights: Wegovy (semaglutide) and Zepbound (tirzepatide 15 mg) — but on June 30, 2026, Novo Nordisk added a Wegovy tablet (oral semaglutide, 1.5/4/9/25 mg) to the Wegovy FDA label, so the injectable-vs-pill picture has changed since this comparison first published^[12]. Wegovy itself now comes in both an injection (2.4 mg weekly, or 7.2 mg “Wegovy HD”) and a tablet (25 mg once daily maintenance). The drugs differ on every dimension that matters to a patient — effect size, delivery, price, titration, side effects, and access. This is the head-to-head with the trial data, the current pricing, and the case for picking each.

The 30-second answer

• Want the biggest weight loss? Zepbound (tirzepatide 15 mg) — 20.9% mean at 72 weeks in SURMOUNT-1^[3].
• Want the cheapest drug if you have commercial insurance? Foundayo with the Lilly Savings Card — $25/month^[1].
• Want the cheapest brand-name injectable self-pay? Wegovy NovoCare at $199/month all-dose subscription^[7].
• Hate needles? There are now two FDA-approved pill options: Foundayo (11.1% at the labeled max, $149–$349/month self-pay) or the Wegovy tablet (13.6% at the labeled max, $149/month for the 1.5–4 mg doses)^[12] — both room-temperature, no refrigeration.
• Have type 2 diabetes too? Zepbound (tirzepatide is also Mounjaro for diabetes — proven A1C reduction).

The drugs at a glance

Three FDA-approved weight management GLP-1 receptor agonists, three different mechanisms and delivery formats. For the full reference list of every FDA-approved and investigational GLP-1 medication on the US market in 2026 — including the seven T2D-only GLP-1s, the three FDA-approved generics (Hikma, Teva, Amneal), and the eight-drug investigational pipeline — see our GLP-1 medication list 2026 full reference .

• Wegovy (semaglutide) — once-weekly subcutaneous injection (2.4 mg, or 7.2 mg “Wegovy HD”). Pure GLP-1 receptor agonist. Approved for chronic weight management since June 2021. As of a June 30, 2026 label update, Wegovy is also available as a once-daily oral tablet (1.5/4/9/25 mg, 25 mg maintenance) for cardiovascular risk reduction or weight reduction in adults^[12] — the tablet is not approved for pediatric weight reduction or for the MASH indication, which remain injection-only. Manufacturer: Novo Nordisk.
• Zepbound (tirzepatide 15 mg) — once-weekly subcutaneous injection. Dual GLP-1 + GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Approved for chronic weight management since November 2023. Manufacturer: Eli Lilly.
• Foundayo (orforglipron) — daily oral tablet. Non-peptide small-molecule GLP-1 receptor agonist (chemically very different from semaglutide and tirzepatide, which are peptide drugs). Approved for chronic weight management on April 1, 2026^[1]. Manufacturer: Eli Lilly.

Effect size — the trial data, head to head

All three drugs were tested in 68-72 week phase 3 obesity trials with similar designs (placebo-controlled, mean BMI ~37, primary endpoint = percent change in body weight). The published mean weight loss results:

• Wegovy injection (STEP-1)^[2] — −14.9% mean weight loss at week 68 vs −2.4% on placebo. n=1,961. About 86% of patients lost ≥5% body weight.
• Zepbound (SURMOUNT-1)^[3] — −20.9% mean at week 72 vs −3.1% placebo. n=2,539. About 91% lost ≥5%. (5 mg dose: −16.0%; 10 mg: −19.5%; 15 mg: −20.9%.)
• Foundayo at the FDA-labeled maximum dose of 17.2 mg in adults without type 2 diabetes — −11.1% mean weight loss (about −24.9 lbs) at 72 weeks per the FDA-approved prescribing information^[11]. ATTAIN-1, the registration trial, excluded adults with type 2 diabetes; the T2D population for orforglipron is being evaluated separately under the ATTAIN-2 / ACHIEVE program.
• Wegovy tablet at the FDA-labeled maintenance dose of 25 mg — −13.6% mean weight loss vs −2.4% placebo (−11.2% treatment difference, 95% CI −13.6 to −8.8, p<0.0001) at 64 weeks in OASIS-4 / Study 7 (NCT05564117), the pivotal trial behind the 2026 tablet approval^[12]. 76.3% of tablet-treated patients lost at least 5% of body weight vs 31.3% on placebo. This makes the tablet's labeled weight-loss claim larger than Foundayo's, though still short of either injectable.

Important note on Foundayo numbers. The ATTAIN-1 phase 3 trial^[10] tested 6, 12, and 36 mg orforglipron arms — not the FDA-approved 17.2 mg labeled maximum. The 36 mg trial arm produced −11.2% on the treatment-regimen (ITT) estimand and −12.4% on the efficacy (completers) estimand. Some third-party marketing pages quote the 36 mg trial result without disclosing it is a supra-labeled dose; the labeled-dose figure (−11.1% at 17.2 mg) is what consumers should expect when prescribed Foundayo.

Two important caveats on direct comparison:

1. These are not head-to-head trials. STEP-1, SURMOUNT-1, and ATTAIN-1 each compared their drug against placebo, not against each other. The only published direct head-to-head between any two of these drugs is SURPASS-2^[9], which compared tirzepatide vs semaglutide in type 2 diabetes (not obesity) and showed tirzepatide's superiority on both A1C and weight loss.
2. Patient populations differ slightly across trials. STEP-1 and ATTAIN-1 enrolled patients with mean BMI ~38; SURMOUNT-1 enrolled patients with mean BMI ~38 as well, but with different prior weight loss attempts and different regional distributions. Effect sizes are comparable but not perfectly interchangeable.

Cost — the 2026 cash-pay landscape

This is where Foundayo changed the market most dramatically when it launched — though by August 2026 the Wegovy tablet has added a second, competitively priced oral option. Pricing verified directly against the manufacturer self-pay programs (NovoCare, LillyDirect) as of August 2026:

Wegovy (injection)

• $199/month introductory NovoCare Pharmacy self-pay price for new patients on the 0.25 mg or 0.5 mg starter dose (2 monthly fills, offer runs through December 31, 2026)
• $349/month standard NovoCare self-pay price for 0.25/0.5/1/1.7/2.4 mg after the introductory fills end
• $399/month for Wegovy HD (7.2 mg)
• List price: $1,349.02/package. With commercial insurance: NovoCare advertises “pay as little as $25/month,” but the savings card caps at $100/month in savings — so out-of-pocket depends on your specific plan's Wegovy copay before the card applies

Wegovy (tablet) — new since the June 2026 label update

• $149/month NovoCare Pharmacy self-pay price for the 1.5 mg and 4 mg tablet doses (the 4 mg introductory price is available through August 31, 2026; after that, 4 mg reverts to $199/month)
• Self-pay pricing for the 9 mg and 25 mg (labeled maintenance) tablet doses was not published on the NovoCare pricing page at the time of this check — verify directly with NovoCare before assuming the $149 starter price extends to the maintenance dose
• Same list price as the injection: $1,349.02/package
• Same insurance savings-card structure as the injection (pay as little as $25/month, capped at $100/month in savings)

Zepbound

• $299/month for the 2.5 mg starter dose via LillyDirect Self Pay (price drop December 1, 2025)
• $399/month for the 5 mg dose
• $449/month for the 7.5 mg and higher doses
• With commercial insurance covering Zepbound: typically $25-$100/month copay

Foundayo

• “As low as $25/month” with the Lilly commercial-insurance savings offer (terms and conditions apply; not Medicare or Medicaid)
• Self-pay pricing is dose-tiered, not flat: starting at $149/month for the 0.8 mg starter dose, $199/month for 2.5 mg, $299/month for 5.5 mg and 9 mg, and $299–$349/month for the 14.5 mg and 17.2 mg (labeled-max) doses depending on refill timing
• No syringes, no needles, no cold chain, no shipping cost structure (it's a pill — distributed through standard pharmacy channels)

The Foundayo “as low as $25/month” commercial-insurance price is still the cheapest legal path to a brand-name FDA-approved GLP-1. But the self-pay price at the labeled-max 17.2 mg dose most patients are eventually titrated to ($299–$349/month) is now close to the Wegovy tablet's starter pricing and well above the flat $149/month this article previously quoted — verify the specific dose tier's price on LillyDirect rather than assuming the starter-dose price applies at maintenance. It remains cheaper than Zepbound's maintenance-dose self-pay tiers ($449/month) and roughly comparable to the Wegovy injection's standard self-pay price ($349/month).

Delivery — pill vs injection

Zepbound is a subcutaneous injection delivered by single-use auto-injector pens, and Wegovy is available both as that same style of injection and, since a June 30, 2026 label update, as an oral tablet^[12]. For the injection route: you inject once a week, you rotate sites, you store the pens in the refrigerator, and you travel with a cooler if you fly. See our step-by-step injection technique guide for the operational details.

Foundayo is a daily oral tablet. No injections, no needle disposal, no refrigeration, no cold chain, no airport pat-down conversation about medical-device exemptions. Per the FDA-approved prescribing information, Foundayo can be taken any time of day, with or without food, and with no water restrictions^[11]. This is the central dosing-experience differentiator from Rybelsus (oral semaglutide), which is a peptide that must be taken on an empty stomach with no more than 4 ounces of water followed by a 30-minute wait before anything else by mouth. Because orforglipron is a non-peptide small molecule, it survives stomach acid and digestion without an absorption enhancer — so the Foundayo label carries none of Rybelsus's food, water, or timing restrictions. The Wegovy tablet lands in between: per its own label, it must be taken on an empty stomach in the morning with no more than 4 ounces of plain water, followed by a 30-minute wait before food, beverages, or other oral medications^[12] — the same restrictive administration pattern as Rybelsus, not Foundayo's food-agnostic dosing. So among the pill options, Foundayo is the only one with zero food/water/timing restrictions; the Wegovy tablet trades a stricter morning routine for a larger labeled weight-loss effect (13.6% vs 11.1%). (Note: per an FDA discontinuation notice dated June 4, 2026, Novo Nordisk is retiring the Rybelsus-branded NDCs and replacing them with tablets branded “Ozempic” — the DailyMed label for the same SetID was updated May 2026 to read “Ozempic (oral semaglutide) tablet / Rybelsus (oral semaglutide) tablet.” It is the same T2D-only oral semaglutide product and food rule under a transitioning brand name, not a new drug.) For the full side-by-side comparison of every FDA-approved oral GLP-1 — Rybelsus/Ozempic tablet vs Foundayo vs the Wegovy tablet — see our GLP-1 pills 2026 comparison .

See our (forthcoming) how to take Foundayo guide for the full daily protocol, food restrictions, and missed-dose rules.

Titration schedule

• Wegovy injection — 5 dose steps: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, with at least 4 weeks between each dose increase per the Wegovy label. Total escalation time to maintenance: ~16-20 weeks.
• Zepbound — 6 dose steps: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with at least 4 weeks between each dose increase per the Zepbound label. Total: ~20-24 weeks. Lower maintenance doses (5 mg or 10 mg) are also FDA-labeled and produce meaningful weight loss, so not every patient escalates to 15 mg.
• Foundayo — 6 dose steps per the FDA label: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, with at least 30 days between each dose increase per the Foundayo prescribing information ^[11]. Total: roughly 6 months to the labeled maximum dose. For a calendar-anchored Days 1-90 walkthrough of what each Foundayo dose feels like in practice, see our Foundayo week-by-week titration guide .
• Wegovy tablet — 4 dose steps per the FDA label: 1.5 mg → 4 mg → 9 mg → 25 mg, with at least 30 days between each dose increase^[12]. Total: roughly 4 months to the 25 mg labeled maintenance dose — faster to maintenance than Foundayo, though on a stricter fasted-morning administration schedule.

All three follow the same general principle of slow upward titration to manage GI side effects. Foundayo's steps are smaller in fractional terms, which may help tolerance.

Side effect profile — the trial-reported rates

All three drugs share the GLP-1 class side effects: nausea, vomiting, diarrhea, constipation, dyspepsia. The trial-reported rates at the maintenance dose:

• Wegovy (STEP-1)^[2] — 44.2% nausea, 24.8% vomiting, 31.5% diarrhea, 23.4% constipation. ~4.5% discontinued for GI side effects.
• Zepbound (SURMOUNT-1)^[3] at the 15 mg dose — approximately 29.0% nausea, 12.2% vomiting, 21.2% diarrhea, 11.7% constipation (SURMOUNT-1 supplementary tables). ~4.3% discontinued for GI.
• Foundayo (ATTAIN-1) — preliminary data suggest a lower nausea rate than Wegovy, similar to or slightly above tirzepatide. The full AE table will be in the published manuscript and the FDA label.

See our GLP-1 nausea management guide for the practical strategies that apply across all three drugs.

Drug interaction profile

All three carry the same boxed warning for medullary thyroid carcinoma based on rodent studies (see our cancer and MTC article ), and all three are contraindicated in MEN2 and personal or family MTC history. The injectable GLP-1s and Foundayo differ on one important interaction:

• Wegovy injection and Zepbound — no specific oral contraceptive warning. PK studies have not shown clinically meaningful reduction in OCP bioavailability for the injectables.
• Wegovy tablet — the label's general drug-interactions section (7.2) notes that Wegovy delays gastric emptying and may impact absorption of concomitant oral medications, recommending increased monitoring for oral drugs with a narrow therapeutic index; it does not carry Foundayo's specific 30-day-after-dose-change contraceptive-method instruction^[12].
• Foundayo — Section 7.1 of the label specifically recommends a non-oral contraceptive method (or barrier backup) for 30 days after starting and 30 days after each dose increase. This is because Foundayo is itself an oral drug and the gastric-emptying-and- absorption interaction is more direct.
• Foundayo + strong CYP3A4 inhibitors — when co-administered with a strong CYP3A4 inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, or ritonavir-boosted antivirals), the Foundayo label caps the maximum daily dose at 9 mg once daily ^[11]. This is a labeled drug-drug interaction warning unique to Foundayo among the three weight-loss GLP-1s.

See our GLP-1 drug interaction checker for the full per-drug interaction database.

Pharmacokinetics and washout

• Wegovy (injection or tablet — same semaglutide molecule) — t½ ~7 days regardless of route. Steady state in 4-5 weeks. Pre-pregnancy washout: 2 months per the label, unchanged by the 2026 tablet addition^[12].
• Zepbound — tirzepatide t½ ~5 days. Steady state in 3-4 weeks. Same 2-month pre-pregnancy washout in clinical practice.
• Foundayo — orforglipron t½ 29-49 hours per the FDA label^[11]. Steady state in approximately 5-10 days (roughly 4-5 half-lives). Much shorter washout than either semaglutide product — useful for pre-procedure hold and pre-pregnancy planning.

Use our GLP-1 washout calculator to see the residual concentration timeline for any of the three drugs.

The case for each drug

Pick Wegovy if...

• You have insurance that covers it on formulary, OR
• You want the injection and the lowest introductory self-pay price on a starter dose ($199/month for the first 2 fills at 0.25/0.5 mg, then $349/month standard), OR
• You want a pill instead of a needle but still want the larger labeled weight-loss number: the Wegovy tablet (25 mg, 13.6% at 64 weeks) beats Foundayo's 11.1%, at a comparable starter self-pay price ($149/month), though on a Rybelsus-style empty-stomach schedule, OR
• You have cardiovascular disease (the SELECT trial showed a 20% reduction in cardiovascular events on semaglutide 2.4 mg, which gave Wegovy a labeled CV benefit indication that Zepbound and Foundayo do not yet have — carried by both the injection and the tablet)

Pick Zepbound if...

• You want the largest expected weight loss (20.9% mean in SURMOUNT-1 vs 14.9% Wegovy injection, 13.6% Wegovy tablet, and 11.1% Foundayo at each drug's labeled max dose)
• You have type 2 diabetes (tirzepatide also exists as Mounjaro for diabetes — same drug, same manufacturer, different label)
• You have obstructive sleep apnea (the SURMOUNT-OSA trial showed tirzepatide reduced sleep apnea severity, and Zepbound has a labeled OSA indication)
• You were forced off Zepbound by an insurance formulary edit (CVS Caremark July 2025 swap, BMI clawback, or denial) and want to understand the realistic alternative paths plus the formulary-exception appeal — see our Zepbound alternatives 2026: Caremark-displaced edition for the rank-ordered playbook.

Pick Foundayo if...

• You have commercial insurance and qualify for the “as low as $25/month” savings offer
• You hate needles and would prefer a daily pill
• You travel frequently and don't want to manage cold chain logistics
• You expect to need short-notice surgery or a procedure (Foundayo's 29-49 hour half-life means a much shorter hold timeline than either semaglutide product, injected or oral)
• You want a drug you can take any time of day with or without food — no empty-stomach rule, no water restrictions, no 30-minute fast before eating (this is what separates Foundayo from the Wegovy tablet, which does carry that fasted-morning rule)
• An ~11% expected weight loss is meaningful enough for your goals (most patients with BMI ≥35 will say yes) — if you want a larger pill-form number and can tolerate a stricter morning routine, compare against the Wegovy tablet's 13.6%

What this comparison is NOT

This is a head-to-head summary, not a clinical recommendation. The right drug for any individual patient depends on their full medical history, comorbidities, insurance situation, lifestyle, and tolerance for the GI side effects in the first 2-4 months. Discuss the choice with a qualified prescriber. This article is informational only.

This article also is not a switching guide. If you are already on one of these drugs and considering a change to another, the FDA labels do not contain a dose-equivalence conversion table — switching is a prescriber decision. For the specific Foundayo ↔ Zepbound switch question (verbatim §2 dose ranges side-by-side, the cross-trial efficacy comparison, the practical re-titration logic, and the oral-contraceptive label-asymmetry that affects patients of reproductive potential), see our companion Foundayo ↔ Zepbound switch dose-equivalence guide . For broader cross-class switching (semaglutide ↔ tirzepatide, brand ↔ compounded, etc.), see the switching between GLP-1 medications guide .

Bottom line

• All are FDA-approved for chronic weight management with BMI ≥30 (or ≥27 with comorbidity); Wegovy (both forms) additionally carries a cardiovascular-risk-reduction indication and, injection-only, a MASH indication and pediatric (12+) weight-reduction indication.
• Effect size at each drug's labeled maximum dose: Zepbound 20.9% > Wegovy injection 14.9% > Wegovy tablet 13.6% > Foundayo 11.1%, on published mean trial data (cross-trial comparison, not head-to-head).
• Cost (commercial insurance): both Foundayo and Wegovy (either form) advertise “as low as $25/month,” though actual out-of-pocket depends on your plan's underlying copay before the manufacturer card applies; Zepbound's commercial-insurance copay is typically $25-$100/month after PA.
• Cost (self-pay, starter dose): Foundayo $149 ≈ Wegovy tablet $149 < Wegovy injection $199 (introductory) < Zepbound $299. At labeled-maximum/maintenance dose, self-pay pricing is closer across the board: Foundayo $299-$349, Wegovy injection $349 standard, Zepbound $449; Wegovy tablet's maintenance-dose self-pay price was not published at last check.
• Delivery: Foundayo is pill-only; Zepbound is injection-only; Wegovy is now available as EITHER a weekly injection OR a daily tablet (since June 2026) — the only one of the three with both options under one brand.
• Unique features: Wegovy (both forms) has a labeled cardiovascular benefit and, injection-only, a MASH indication; Zepbound has a labeled OSA indication; Foundayo has no food/water/timing restrictions at all, the only pill in this comparison without a fasted-morning rule.

Related research and tools

• What is the best GLP-1 for weight loss? Ranked by FDA evidence (2026) — the cross-class ranking that places this Foundayo / Wegovy / Zepbound three-way comparison in the broader four-drug + retatrutide-pipeline context, with the criterion-by-criterion decision framework (magnitude, cardiovascular outcomes, oral route, cost).
• Compounded tirzepatide vs compounded semaglutide — if you are considering the compounded route instead of brand-name Wegovy or Zepbound: molecule differences, fridge life (28–90 day pharmacy BUD), regulatory status post-Feb 2025, and the SURMOUNT-5 efficacy comparison with cross-trial caveat
• Where to inject tirzepatide (Zepbound / Mounjaro) — the 3 FDA-approved injection sites, rotation rules to prevent lipohypertrophy, and step-by-step pen vs vial technique
• Weight loss injections guide 2026 — every FDA-approved injectable (Wegovy, Zepbound, Saxenda), head-to-head SURMOUNT-5 data, verbatim FDA safety warnings, and verified cash-pay pricing
• Rybelsus alternatives: when oral semaglutide isn't working — switching to Foundayo, Wegovy, or Zepbound when the T2D-only oral GLP-1 isn't producing the weight loss patients wanted
• GLP-1 Drug Decision Quiz — 4-step quiz: BMI + comorbidity + form preference → FDA-approved drug match with cited trial evidence
• Foundayo (orforglipron) approval deep-dive — the full ATTAIN-1 trial review and approval narrative
• How to take Foundayo — daily protocol, food restrictions, missed dose rules
• How to get a GLP-1 prescription in 2026 — buyer funnel for all four paths
• Wegovy vs Ozempic vs Zepbound vs Mounjaro brand name cheat sheet
• Tirzepatide vs semaglutide head-to-head — the SURPASS-2 direct comparison
• GLP-1 savings calculator 2026 — compare 10 access paths over 1, 5, and 10 years
• GLP-1 weight loss calculator — STEP-1 / SURMOUNT-1 / ATTAIN-1 trial-data-backed predictor
• GLP-1 BMI calculator — eligibility check + outcome overlay for all three drugs
• GLP-1 drug interaction checker
• Tennessee Medicaid (TennCare) GLP-1 coverage (2026): Wegovy + Zepbound both Preferred — TennCare is among the most favorable state Medicaid programs for accessing both Wegovy and Zepbound with verifiable Preferred-PDL status, FDA-label-aligned BMI criteria, and a 1-year initial PA window. Foundayo (orforglipron) does not bill insurance and is not a TennCare pathway.
• When to increase your Mounjaro dose for weight loss (titration decision guide) — if you are on Zepbound or off-label Mounjaro and wondering when to move up the dose ladder: FDA Section 2 verbatim, SURMOUNT-1 protocol, and the 4-condition framework

Further reading

• Wegovy vs Zepbound matchup
• SURMOUNT-5 trial deep-dive (tirzepatide vs semaglutide head-to-head)
• Top tirzepatide weight-loss studies (curated PubMed reading list)
• Top oral-GLP-1 questions on Reddit, answered
• PIONEER 6 trial deep-dive (oral semaglutide cardiovascular outcomes)